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Abstract
There is a paucity of data characterizing right ventricular performance in heart failure with preserved ejection fraction 
(HFpEF) using the gold standard of cardiovascular magnetic resonance imaging (CMR). We aimed to assess the proportion 
of right ventricular systolic dysfunction (RVD) in HFpEF and the relation to clinical outcomes. As part of a single-centre, 
prospective, observational study, 183 subjects (135 HFpEF, and 48 age- and sex-matched controls) underwent extensive 
characterization with CMR. transthoracic echocardiography, blood sampling and six-minute walk testing. Patients were fol-
lowed for the composite endpoint of death or HF hospitalization. RVD (defined as right ventricular ejection fraction < 47%) 
controls was present in 19% of HFpEF. Patients with RVD presented more frequently with lower systolic blood pressure, 
atrial fibrillation, radiographic evidence of pulmonary congestion and raised cardiothoracic ratio and larger right ventricular 
volumes. During median follow-up of 1429 days, 47% (n = 64) of HFpEF subjects experienced the composite endpoint of 
death (n = 22) or HF hospitalization (n = 42). RVD was associated with an increased risk of composite events (Log-Rank 
p = 0.001). In multivariable Cox regression analysis, RVD was an independent predictor of adverse outcomes (adjusted Haz-
ard Ratio [HR] 3.946, 95% CI 1.878–8.290, p = 0.0001) along with indexed extracellular volume (HR 1.742, CI 1.176–2.579, 
p = 0.006) and E/E’ (HR 1.745, CI 1.230–2.477, p = 0.002). RVD as assessed by CMR is prevalent in nearly one-fifth of 
HFpEF patients and is independently associated with death and/or hospitalization with HF.
The trial was registered retrospectively on ClinicalTrials.gov (Identifier: NCT03050593). The date of registration was Feb-
ruary 06, 2017.
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Introduction
The importance of right ventricular (RV) function and 
its impact upon functional status [1] and outcomes [2] in 
heart failure with reduced ejection fraction (HFrEF) is 
well established. However, heart failure with preserved 
ejection fraction (HFpEF) currently accounts for approxi-
mately half of all cases of heart failure [3] and the role of 
right ventricular systolic dysfunction (RVD) in this set-
ting is less well studied. To date, the majority of evidence 
for RVD is largely derived from echocardiographic data 
[4]. Moreover, the reported prevalence of RVD in HFpEF 
varies depending upon the choice of RV assessment tool 
and differing diagnostic thresholds (e.g. tricuspid annular 
plane systolic excursion [TAPSE], fractional area change 
[FAC], right ventricular ejection fraction [RVEF]) [5].
Cardiovascular magnetic resonance imaging (CMR) is 
the gold standard for RV volumetric and functional assess-
ment, providing excellent accuracy and reproducibility [6, 
7]. However, only 2 CMR studies [8, 9] have assessed 
RV function in in HFpEF, again with differing thresholds 
for RVD and both lacking reference control groups. All 
of the above observations were recognized in a position 
statement from the Heart Failure Association of the Euro-
pean Society of Cardiology, proposing further prospective 
outcome studies to identify clear cut-off values for RVD 
that are prognostically and clinically relevant [4]. In our 
prospective, observational study comprising both groups 
of HFpEF and age- and sex-matched healthy subjects, we 
aimed to assess the proportion of patients with RVD and 
explored the relation to clinical outcomes.
Materials and methods
Study population
HFpEF patients were recruited as part of the Developing 
Imaging And plasMa biOmarkers iN Describing HFpEF 
(DIAMOND-HFpEF) study: an observational, cohort 
study conducted at a single tertiary cardiac centre [10]. 
The National Research Ethics Service approved the study. 
All subjects provided written informed consent prior to 
participation. As detailed previously [11, 12] HFpEF 
inclusion criteria were: clinical or radiographic evidence 
of heart failure (HF), left ventricular (LV) ejection frac-
tion (EF) > 50% on transthoracic echocardiography (TTE) 
and age ≥ 18 years. Exclusion criteria were: known myo-
cardial infarction (MI) in the preceding 6 months; sus-
pected or confirmed cardiomyopathy or constrictive peri-
carditis; non-cardiovascular life expectancy < 6 months; 
severe native valve disease; severe lung disease (or forced 
expiratory volume  [FEV1] < 30% predicted or forced vital 
capacity [FVC] < 50% predicted); estimated glomerular 
filtration rate (eGFR) < 30 ml/min/m2 and standard con-
traindications to CMR.
A control group of 48 asymptomatic, age- and sex-
matched subjects without known cardiac disease were also 
recruited. Since hypertension is highly prevalent in the gen-
eral population without heart failure and is also strongly 
associated with incident HFpEF development, we included 
a subset of hypertensive controls (n = 22) in order to account 
for this potential confounder. All study participants under-
went comprehensive clinical evaluation, blood sampling, 
TTE, six-minute walk testing (6MWT) and CMR during a 
solitary study visit.
Blood sampling
Blood was sampled for measurement of B-type natriuretic 
peptide (BNP; immunoassay, Siemens, Erlangen, Ger-
many), haematocrit, haemoglobin and renal function (urea, 
creatinine).
Transthoracic echocardiography
As reported previously [11, 12] image acquisition and analy-
sis was undertaken by 2 experienced, accredited sonogra-
phers using an iE 33 system with S5-1 transducer (Philips 
Medical Systems, Best, The Netherlands). Echocardiogra-
phy was performed primarily to confirm preserved LVEF 
for study inclusion and E/E′ was also calculated to assess 
LV filling pressure.
Functional assessment of exercise capacity
To provide an objective metric of exercise capacity, the 
6MWT distance was measured in all subjects according to 
standardized protocols [13].
Chest radiography
The radiology reports of the most recent chest X-ray prior to 
the study visits were sourced from the hospital computerized 
reporting system [10]. The presence of pulmonary conges-
tion and an enlarged cardiothoracic ratio were recorded. All 
reporting was done by Radiologists blinded to study partici-
pation and prior to subject enrolment.
CMR protocol
The CMR protocol used has been reported previously [11, 
14, 15]. All scans were performed on a 3 T scanner (Siemens 
Skyra, Erlangen, Germany) with an 18-channel cardiac coil. 
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In summary, the protocol included: conventional long- and 
short-axis cine images covering the LV and RV; pre- and 
post-contrast T1 mapping of basal, mid and apical LV slices; 
and late gadolinium enhancement (LGE) imaging. The total 
contrast dose administered was 0.15 mmol/kg of Gadovist 
(Bayer Healthcare, Berlin, Germany).
CMR image analysis
Cine images were analyzed using semi-automated cvi42 
software (Circle Cardiovascular Imaging, Calgary, Canada) 
by a single experienced observer (PK), blinded to all clini-
cal data. All volumetric and mass data were indexed to body 
surface area (BSA). Ventricular volumes (see Fig. 1), ejec-
tion fraction and LV mass (excluding papillary muscles) 
were calculated from the short-axis cine stack as previ-
ously described [10, 15]. The biplane method, excluding 
the appendage and pulmonary veins was used to measure 
maximal, minimal left atrial volumes (LAVmax, LAVmin) 
and derive left atrial ejection fraction (LAEF) [11]. A cut-
off RVEF value of < 47% was used to define RVD based 
upon existing normative data from the published literature 
utilizing the same technique as in our study [16] as well 
as from our own healthy control data whereby the lower 
limit of RVEF was also 47%. Qualitative LGE assessment 
was undertaken by 2 experienced operators to define the 
presence of MI as per standard criteria [15, 17]. In cases 
of disagreement, final adjudication was deferred to a third 
operator (GPM). As previously reported by our group with 
excellent reproducibility [18] and intra/inter-observer agree-
ments [15], extracellular volume (ECV) and indexed ECV 
were quantified from mid short-axis LV slice T1 maps.
Outcome data
All participants were followed up for the primary endpoint, 
a composite of all-cause mortality or HF hospitalization 
(defined as a hospital admission for HF which required diu-
retic, inotropic or intravenous nitrate therapy). In patients 
experiencing multiple events, the time to first event was 
used as the censored outcome. Outcome data were obtained 
from Hospital databases. All patients had a minimum of 
12 months follow-up, post study entry.
Statistical analysis
Statistical analyses were performed using SPSS V22. A p 
value of < 0.05 was considered significant. Normality for 
continuous data was assessed using histograms, Q-Q plots 
and the Shapiro–Wilk test. Continuous data are presented 
as mean (± standard deviation) or median (25–75% inter-
quartile range or range). Categorical data are presented as 
absolute numbers or percentages. Between group differences 
were compared using the t test, Mann–Whitney U test and 
the Chi-square test as appropriate. BNP, creatinine, 6MWT 
distance and RVEF were  log10 transformed before analysis.
Spearman’s rank correlations were performed to check 
for important associations of other continuous variables 
Fig. 1  Assessment of ventricular volumes, function and mass. End-
diastolic (a) and end-systolic (b) cine frames illustrating manu-
ally drawn contours of the left ventricular endocardium (pink), left 
ventricular epicardium (green) and right ventricular endocardium 
(yellow) for volumetric and mass analysis. (white arrows) papillary 
muscles and trabeculations were excluded from left ventricular mass 
calculations
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with RVEF. Intra-observer and inter-observer variability 
assessments for RV parameters were undertaken (by PK 
and JRA), a minimum of 4 weeks apart on 10 randomly 
selected patients.
Event rates were calculated from Kaplan–Meier survival 
analysis. Survival curve differences were assessed using the 
Log-Rank test. Univariable Cox regression modeling was 
initially performed to identify variables associated with out-
comes. Only parameters associated with endpoints at p < 0.1 
were entered into subsequent multivariable analysis to iden-
tify independent predictors using both backwards and for-
wards stepwise elimination methods. In cases of collinearity, 
only variables with the highest coefficients or which have 
shown historically stronger prognostic importance based 
upon published literature were entered into multivariable 
analysis. To further minimize over-fitting, Cox regression 
models were limited to one parameter per approximately 
10 composite events. Four separate, clinically relevant 
models were created including a final model comprising 
the strongest predictors. Continuous variables were further 
Z-standardized to enable comparison of hazard ratios (HR) 
based upon one standard deviation increase in the predictor 
variable. The accuracy of the final independent Cox model 
to predict events was then tested by receiver operator char-
acteristics (ROC) analysis.
Results
Two hundred and thirty two subjects were enrolled (HFpEF 
n = 182, controls n = 50), of whom 49 were excluded (see 
Fig. 2) from further analysis. Of these, RV assessment could 
not be performed in 5 patients due to degraded image qual-
ity. Our final cohort who underwent RV analysis comprised 
a total of 183 participants (HFpEF n = 135, controls n = 48). 
As previously reported, iECV calculation was not possible 
(HFpEF n = 43, controls n = 4) in a small subset due to the 
unavailability of the sequences for T1 mapping [15]. Both 
intra-observer and inter-observer variability were excellent 
for RV parameters [10]. All subjects were recruited over 
a period of 26 months. The final participant was enrolled 
in April 2015. Follow-up was until January 2019. Baseline 
demographic features of patients with HFpEF and control 
subjects are shown in Table1; imaging data are in Table 2.
Comparison of HFpEF and controls
Overall, HFpEF and healthy controls were well matched 
for age (73 ± 9 years) and sex. Approximately two-thirds of 
HFpEF patients had experienced prior hospitalization for 
HF or had radiographic evidence of pulmonary congestion. 
Fig. 2  Study recruitment overview. Flow chart illustrating recruitment and reasons for exclusion. CMR cardiovascular magnetic resonance imag-
ing, HFpEF heart failure with preserved ejection fraction, RV right ventricle
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HFpEF was frequently associated with co-morbidities 
including obesity, diabetes, hypertension, atrial fibrillation 
(AF), renal dysfunction and anaemia. Significant minorities 
of HFpEF also had known ischaemic heart disease (22%) 
and lung disease (16%). Furthermore, HFpEF patients had 
worse exercise capacity (shorter 6MWT distance) and nearly 
a third were classed as NYHA III/IV.
Metrics of diastolic dysfunction (BNP, E/E’), and LV 
mass) were higher in HFpEF. Compared to control subjects 
(58 ± 5%), LVEF was marginally lower in HFpEF (56 ± 5%, 
Table 1  Baseline clinical characteristics
Values are mean ± SD or n (%) or median (interquartile range). The p values are for the t-test, Mann–Whitney U test or Chi-square test as appro-
priate
ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, BNP B-type natriuretic peptide, CMR cardiovascular mag-
netic resonance imaging, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, NA not applicable or not assessed, NYHA 












 Age (years) 73 ± 5 72 ± 9 0.521 72 ± 9 75 ± 11 0.183
 Male (%) 24 (50) 66 (49) 0.895 51 (46) 15 (60) 0.218
Clinical findings
 Heart rate (b.p.m.) 68 ± 10 70 ± 14 0.195 70 ± 14 70 ± 14 0.991
 Systolic BP (mmHg) 151 ± 24 145 ± 25 0.193 147 ± 25 136 ± 26 0.042
 Diastolic BP (mmHg) 79 ± 10 74 ± 12 0.016 74 ± 12 74 ± 14 0.924
 Body mass index (kg/m2) 25 ± 3 34 ± 7 < 0.0001 34 ± 7 33 ± 7 0.623
 Sinus rhythm (%) 48 (100) 94 (70) < 0.0001 82 (75) 12 (48) 0.009
 Atrial fibrillation (%) 0 (0) 41 (30) < 0.0001 28 (25) 13 (52) 0.009
Medical history
 Prior hospitalization with heart failure NA 89 (66) NA 67 (61) 22 (88) 0.010
 Diabetes (%) 0 (0) 67 (50) < 0.0001 54 (49) 13 (52) 0.793
 Hypertension (%) 22 (46) 122 (90) < 0.0001 97 (88) 25 (100) 0.071
 Angina (%) 0 (0) 22 (16) 0.003 18 (16) 4 (16) 0.965
 Known myocardial infarction (%) 0 (0) 15 (11) 0.016 13 (12) 2 (8) 0.583
 Known coronary artery disease (%) 0 (0) 30 (22) < 0.0001 24 (22) 6 (24) 0.813
 Asthma or COPD (%) 3 (6) 21 (16) 0.101 16 (15) 5 (20) 0.497
 Smoking (%) 17 (35) 71 (53) 0.041 59 (54) 12 (48) 0.610
Hypercholesterolameia (%) 18 (38) 68 (50) 0.125 56 (51) 12 (48) 0.793
 Peripheral vascular disease (%) 0 (0) 3 (2) 0.298 2 (2) 1 (4) 0.504
 TIA or CVA (%) 1 (2) 19 (14) 0.005 16 (15) 3 (1) 0.770
Medication
 Betablocker (%) 2 (4) 93 (69) < 0.0001 72 (65) 21 (84) 0.071
 ACEi or ARB (%) 10 (21) 116 (86) < 0.0001 95 (86) 21 (84) 0.759
 Aldosterone antagonist (%) 0 (0) 42 (31) < 0.0001 32 (29) 10 (40) 0.288
 Loop diuretic (%) 0 (0) 108 (80) < 0.0001 86 (78) 22 (88) 0.268
Functional status
 NYHA I/II (%) NA 95 (70) NA 80 (75) 15 (60) 0.208
 NYHA III/IV (%) NA 40 (30) NA 30 (27) 10 (40) 0.208
 Six minute walk distance (m) 380 (350–440) 185 (120–250) < 0.0001 190 (130–250) 180 (100–260) 0.633
Bloods
 Sodium (mmol/l) 140.4 ± 1.7 139.3 ± 3.5 0.007 139.2 ± 3.3 139.6 ± 4.2 0.661
 Urea (mmol/l) 6.1 ± 1.5 8.3 ± 3.4 < 0.0001 8.4 ± 3.4 8.0 ± 3.5 0.613
 Creatinine (mmol/l, IQR) 70.5 (56.3–84.5) 88 (73–113) < 0.0001 90 (73–116) 84 (70–108) 0.283
 Haemoglobin (g/l) 140 ± 15 129 ± 22 < 0.0001 129 ± 22 127 ± 21 0.658
 BNP (ng/l, IQR) 33 (24–44) 136 (65–256) < 0.0001 134 (54–269) 170 (84–245) 0.428
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p = 0.019), albeit preserved overall. More concentric remod-
eling (higher LV mass/volume) and diffuse fibrosis (iECV) 
was also evident in HFpEF. LA remodeling (higher LAVI-
max, LAVImin) and dysfunction (lower LAEF) was highly 
prevalent in HFpEF, irrespective of cardiac rhythm. RVEF 
in the control group had a narrow range (median 55, 47–70) 
in contrast to HFpEF (median 54, 27–73), but the difference 
was not statistically significant (p = 0.090). No significant 
differences in RV volumes between HFpEF and controls 
were noted.
Comparison of HFpEF with and without RVD
RVD (was present in nearly one-fifth (19%, n = 25) of 
patients with HFpEF. Compared to patients without RVD, 
those with RVD presented more frequently with lower 
systolic blood pressure, AF, radiographic evidence of 
pulmonary congestion and elevated cardiothoracic ratio. 
RVD was associated with larger right ventricular and LA 
(LAVImin) volumes, and lower LAEF (irrespective of AF 
or sinus rhythm). Furthermore, prior hospitalization with 
decompensated HF was also more prevalent in this sub-
group. There were no statistically significant differences 
between groups in terms of medical history, biochemical 
profiles and prescribed cardiac pharmacotherapies. While 
measures of functional status were worse in the RVD group 
i.e. greater proportion of NYHA III/IV and shorter 6 MWT 
distance walked, these differences did not reach statistical 
significance.
Correlates of RVEF
Statistically significant correlations of RVEF with other 
variables are shown in Table 3. Positive correlations were 
Table 2  Baseline imaging characteristics
Values are mean ± SD or n (%). The p values are for the t-test, Mann–Whitney U test or Chi-square test as appropriate
CTR cardiothoracic ratio, iECV indexed extracellular volume, LAEF left atrial ejection fraction, LAVI left atrial volume indexed to body surface 
area (maximal/minimal), LGE late gadolinium enhancement, LVMI left ventricular end-diastolic mass indexed to body surface area, LVEDVI left 
ventricular end-diastolic volume indexed to body surface area, MI myocardial infarction, NA not applicable or not assessed, RVEF right ventricu-
lar ejection fraction, RVEDVI right ventricular end-diastolic volume indexed to body surface area, RVESVI right ventricular end-systolic volume 












 Pulmonary congestion (%) NA 93 (69) NA 71 (65) 22 (88) 0.025
 Raised CTR (%) NA 98 (73) NA 75 (68) 23 (92) 0.018
 Pleural effusion (%) NA 48 (36) NA 36 (33) 12 (48) 0.159
Echo
 E/E′ 9 ± 3 13 ± 5 < 0.0001 13 ± 5 13 ± 6 0.723
CMR
 LVEF (%) 58 ± 5 56 ± 5 0.019 56 ± 5 55 ± 6 0.449
 LVEDVI (ml/m2) 81 ± 14 79 ± 18 0.409 79 ± 19 77 ± 16 0.493
 LVMI (g/m2) 46 ± 9 52 ± 15 < 0.0001 52 ± 16 52 ± 10 0.886
 LV mass/LV volume 0.57 ± 0.09 0.68 ± 0.16 < 0.0001 0.67 ± 0.16 0.70 ± 0.15 0.447
 RVEF (%), median, range 55 (47–70) 54 (27–74) 0.090 56 (47–74) 44 (27–46) < 0.0001
 RVEDVI (ml/m2) 83 ± 15 80 ± 19 0.307 76 ± 16 98 ± 20 < 0.0001
 RVESVI (ml/m2) 37 ± 9 37 ± 14 0.849 33 ± 10 57 ± 15 < 0.0001
Overall
 LAEF (%) 51 ± 11 32 ± 16 < 0.0001 35 ± 15 22 ± 12 < 0.0001
 LAVImax (ml/m2) 35 ± 12 53 ± 25 < 0.0001 51 ± 23 62 ± 31 0.054
 LAVImin (ml/m2) 17 ± 8 38 ± 25 < 0.0001 36 ± 23 49 ± 31 0.017
Sinus rhythm
 LAEF (%) 51 ± 11 41 ± 12 < 0.0001 42 ± 11 32 ± 10 0.006
 LAVImax (ml/m2) 35 ± 12 43 ± 16 0.003 43 ± 16 44 ± 17 0.854
 LAVImin (ml/m2) 17 ± 8 26 ± 13 < 0.0001 25 ± 13 30 ± 15 0.243
 Presence of MI on LGE (%) 0 (0) 23 (17) 0.002 17 (15) 6 (24) 0.305
 iECV (ml/m2) 10.9 ± 2.8 13.7 ± 4.4 < 0.0001 13.5 ± 4.5 14.7 ± 3.7 0.276
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observed with LVEF and LAEF. Inverse relationships were 
seen for RVEF with RV, LV and LA volumes. The strongest 
correlations were with RV volumes (right ventricular end-
systolic volume indexed [RVESVI] r = − 0.788, right ven-
tricular end-diastolic volume indexed [RVEDVI r = − 0.392] 
and LAEF r = 0.441).
RVD and outcomes
During median follow-up of 1429 days (1153–1654), 47% 
of HFpEF subjects (n = 64) experienced the composite end-
point of death (n = 22) or hospitalization with HF (n = 42). 
There were no events in the control group.
Kaplan–Meier survival curves stratified according to 
the presence or absence of RVD in HFpEF are shown in 
Fig. 3. HFpEF patients with RVD had significantly higher 
event rates (Log-Rank p = 0.001). Furthermore, in those 
HFpEF patients with RVD, when stratified into tertiles 
on the basis of RVEF (see online Resource Supplemen-
tary Fig. 1), the lower RVEF groups were associated with 
increasing risk of HF hospitalizations, albeit statistical 
significance was not reached (Log-Rank p = 0.170). On 
univariable Cox regression analysis (Table 4), nineteen 
parameters were associated with adverse outcomes: 
age, diastolic blood pressure, prior HF hospitalization, 
NYHA III/IV, Log 6MWT distance, Log creatinine, hae-
moglobin, Log BNP, E/E’, left ventricular mass indexed 
(LVMI), LAVImax, LAEF, presence of MI on LGE, ECV 
indexed ECV, RVEDVI, RVESVI, Log RVEF and RVD. 
Of these, 4 parameters were excluded from multivariable 
analysis. During multivariable analysis (see Table 5), 
RVD remained significantly associated with outcomes 
in 3 separate models incorporating either: clinical, bio-
chemical or imaging metrics. In a final model comprising 
the strongest parameters overall, RVD remained an inde-
pendent predictor of outcomes (adjusted Hazard Ratio 
[HR] 3.946, 95% CI 1.878–8.290, p = 0.0001) along with 
indexed ECV (HR 1.742, CI 1.176–2.579, p = 0.006) 
and echocardiographic E/E’ (HR 1.745, CI 1.230–2.477, 
p = 0.002). The final Cox model incorporating these 3 
Table 3  Significant associations of RVEF with other continuous vari-
ables




Systolic BP (mmHg) 0.321 < 0.0001
LVEDVI (ml/m2) 0.174 0.044
LVEF (%) 0.219 0.011
RVEDVI (ml/m2) − 0.392 < 0.0001
RVESVI (ml/m2) − 0.788 < 0.0001
LAVImax (ml/m2) − 0.175 0.043
LAVImin (ml/m2) − 0.272 0.001
LAEF (%) 0.441 < 0.0001
Fig. 3  Survival analysis stratified according to the presence or 
absence of right ventricular dysfunction. Kaplan–Meier analysis for 
the composite endpoint of death and/or hospitalization with heart fail-
ure; RVD right ventricular dysfunction
Table 4  Unadjusted predictors for the composite endpoint of death 
and/or hospitalization with heart failure
a Parameters not entered into multivariable analysis; Abbreviations are 
as per Tables 1 and 2
Unadjusted predictors of outcome
Hazard ratio (95%CI) p value
Clinical
 Age (years) 1.406 (1.068–1.851) 0.015
 Average diastolic BP (mmHg) 0.660 (0.505–0.863) 0.002
 Prior HF hospitalization 3.332 (1.735–6.399) 0.0001
 NYHA III/IV 1.747 (1.054–2.894) 0.030
 Log 6MWT distance (m) 0.739 (0.580–0.941) 0.014
 Clinical blood samples
 Log creatinine (μmol/l) 1.281 (1.021–1.607) 0.032
 Haemoglobin (g/l) 0.711 (0.550–0.920) 0.009
 Log BNP (ng/l) 1.437 (1.093–1.889) 0.009
Imaging
 LV mass index (g/m2) 1.284 (1.028–1.605) 0.028
 LAVImax (ml/m2) 1.310 (1.044–1.643) 0.020
 Biplane LAEF (%) 0.737 (0.578–0.938) 0.013
 LGE MI (%) 1.745 (0.963–3.159) 0.066
 RVEDVI (ml/m2)a 1.292 (1.001–1.668) 0.049
 RVESVI (ml/m2)a 1.305 (1.035–1.645) 0.024
 Log RVEF (%)a 0.819 (0.650–1.030) 0.088
 RVD 2.533 (1.452–4.419) 0.001
 ECV (%)a 1.578 (1.144–2.178) 0.005
 iECV (ml/m2) 1.546 (1.128–2.119) 0.007
 E/E′ 1.420 (1.118–1.804) 0.004
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independent variables to predict outcome yielded an area 
under the ROC curve of 0.732, p < 0.0001.
Discussion
This is the first prospective study to analyze RV systolic 
performance and remodeling with CMR in both age- and 
sex-matched HFpEF and control groups. The principal 
findings in our study are that in HFpEF: (1) RVD is pre-
sent in a significant minority; (2) RVEF is associated with 
RV/LV/LA volumes and LA function; and (3) RVD is 
independently associated with the risk of death or re-
hospitalization with HF.
Prevalence of RVD
To date, the reportedly wide range of prevalence of RVD 
in HFpEF of 4 to 44% has been derived almost exclusively 
from echocardiographic data [5]. Factors implicated in this 
variation in prevalence include the differing populations 
studied (community based, registry data, clinical trials) 
and variable definitions of both HFpEF (LVEF ≥ 45% and 
LVEF > 50%) and RVD [4, 5]. Besides, the complex geom-
etry of the RV renders it a difficult chamber to assess with 
traditional 2D echocardiography, especially in the context 
of HFpEF when imaging may be more challenging due to 
co-morbidites such as lung disease, obesity and AF [4].
CMR is the established gold standard for RV assessment 
[6, 7]. To date, only one prior CMR study [8] has reported 
prevalence (19%) of RVD in HFpEF, using a RVEF cut-off 
of < 45%, primarily based upon ARVC guidelines [19]. In 
contrast, we observed a similar prevalence using a slightly 
higher RVEF cut-off of RVEF < 47% based on our own inter-
nal reference controls, a particular strength of our study.
Significance of RVD in HFpEF, causes and possible 
mechanisms implicated in outcomes
In HFrEF, the presence of RVD portends poorer functional 
status, exercise capacity [1, 20] and prognosis [2]. However, 
a similar association of RVD with outcomes in HFpEF has 
not been observed consistently. In echocardiographic stud-
ies of community [21] and hospital based HFpEF subjects 
referred for invasive right heart catheterization [22], RVD 
was independently predictive of mortality. To the contrary, 
in a larger observational study [23] comprising outpatient 
HFpEF recruits and in the TOPCAT clinical trial [24], 
RVD did not adversely impact upon prognosis. The likely 
explanation for these differences include: variable HFpEF 
LVEF cut-offs, use of different parameters to define RVD 
as described earlier and more stringent exclusion criteria in 
clinical trials compared to community settings such as renal 
dysfunction or coronary artery disease which have been 
shown to be associated with RVD [4] but are also indepen-
dently associated with increased risk [25].
Our work however adds to findings from the only 2 CMR-
based HFpEF outcome studies to date [8, 9] and clearly 
implicates RVD as an important mediator of outcomes in 
HFpEF. In the first study [9], all surrogates of RVD, irre-
spective of modality (CMR, echocardiography and invasive 
right heart catheterization) were associated with death and or 
HF hospitalization during univariable analysis. In the above 
study (n = 142, median follow-up 10 months), a much lower 
CMR measured RVEF cut-off (< 35%) was used to define 
RVD in contrast to our study. However, this association with 
outcomes was not significant for CMR RVD during multi-
variable analysis, following adjustment for clinical variables. 
Table 5  Multiple Cox regression models inclusive of RVD for the 
composite endpoint of death and/or hospitalization with heart failure
Abbreviations are as per Tables 1 and 2
Adjusted predictors of outcome
Hazard ratio (95%CI) p value
Clinical (Model 1)
 Age (years) 1.247 (0.925–1.679) 0.147
 Average Diastolic BP (mmHg) 0.735 (0.572–0.944) 0.016
 Prior HF hospitalization 2.671 (1.360–5.245) 0.004
 NYHA III/IV 0.869 (0.391–1.929) 0.729
 Log 6MWT distance (m) 0.883 (0.665–1.173) 0.392
+RVD 1.873 (1.054–3.327) 0.032
Clinical blood samples (model 2)
 Log Creatinine (μmol/l) 1.296 (1.034–1.624) 0.025
 Haemoglobin (g/l) 0.764 (0.591–0.987) 0.040
 Log BNP (ng/l) 1.228 (0.925–1.630) 0.155
+RVD 2.495 (1.419–4.384) 0.001
Imaging (model 3)
 LV mass index (g/m2) 0.848 (0.360–2.000) 0.707
 LAVImax (ml/m2) 0.742 (0.414–1.332) 0.318
 Biplane LAEF (%) 0.827 (0.575–1.189) 0.306
 LGE MI (%) 1.374 (0.526–3.590) 0.516
 iECV (ml/m2) 1.742 (1.176–2.579) 0.006
 E/E′ 1.745 (1.230–2.477) 0.002
 + RVD 3.946 (1.878–8.290) 0.0001
Strongest markers combined (model 4)
 Average diastolic BP (mmHg) 1.306 (0.890–1.916) 0.172
 Prior HF hospitalization 2.094 (0.875–5.011) 0.097
 Log creatinine (μmol/l) 1.343 (0.929–1.941) 0.116
 Haemoglobin (g/l) 0.983 (0.634–1.525) 0.940
 iECV (ml/m2) 1.742 (1.176–2.579) 0.006
 E/E′ 1.745 (1.230–2.477) 0.002
+ RVD 3.946 (1.878–8.290) 0.0001
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On the other hand echocardiographic (RV systolic function, 
estimated pulmonary artery systolic pressure [PASP]) and 
invasive (measured PASP, pulmonary capillary wedge pres-
sure [PCWP]) metrics of RVD remained independent pre-
dictors of adverse outcomes. In the second study (n = 171, 
median follow-up 573 days), RVD measured by CMR out-
performed echocardiographic-derived measures of RVD as 
a prognostic marker [8]. The RVEF cut-off to define RVD 
(< 45%) was also chosen based upon ROC analysis to detect 
end-points. In contrast to both of the aforementioned studies, 
our follow-up times were substantially longer, the mere pres-
ence of RVD and not just more severe RVD was significantly 
associated with worse outcomes in our cohort. Furthermore, 
our definition of RVD was based upon reference control 
data, again lacking in both of these prior studies.
In line with previous studies, the RVD sub-group in our 
HFpEF cohort was also noted to have lower systolic blood 
pressure, more frequent AF [26, 27], higher frequency of 
prior HF hospitalizations [21], a greater of adverse RV 
remodeling (RV enlargement) [27] and more prevalent pul-
monary congestion [28]. There are likely multiple reasons 
for these findings which appear intimately linked. RV con-
tractile function is intrinsically related to RV volumes, as 
also demonstrated by the moderate to strong inverse cor-
relations of RVEF with RV volumes in our study. Further-
more, increasing RV size is an independent predictor of 
incident RVD development in HFpEF [27], analogous to 
that observed in similar LV pressure overloaded conditions 
such as aortic stenosis [29]. These factors either in isola-
tion or when coupled together are known to be associated 
with increased venous congestion [28] as also shown by the 
higher rates of congestive chest radiographic changes in our 
RVD subjects. Increasing congestion is a major cause of 
HF hospitalization and therefore likely explains the observa-
tion of both prior HF hospitalization as well the association 
with re-hospitalization with HF (as a part of the composite 
end-point) seen in our RVD sub-group. Both the RVD sub-
jects from our cohort and from previous studies [8, 9] also 
demonstrate an association with increased LA size, a sur-
rogate marker of high LA pressure, which likely portends 
congestion. Furthermore, the RVD group also had a greater 
proportion of AF, which is known to further exacerbate RV 
contractile dysfunction [22, 26, 27] and provoke circula-
tory collapse [20] likely necessitating HF hospitalizations 
[30]. Our study is also the first to demonstrate an associa-
tion between CMR RVEF and LAEF which likely further 
compounds the above features and has been hypothesized 
previously from echocardiographic data [22].
Other authors have previously suggested a clear relation-
ship between RVD and the severity of left heart disease as 
reflected by NYHA class, natriuretic peptides or LV systolic 
function [5]. However, in our study, these parameters were 
not different between those with and without RVD. This may 
merely be a reflection of our sample size. Alternatively, RVD 
may be part of the aetiological profile in HFpEF whereby 
biventricular remodeling often co-exists, even in early 
stages [31] or driven by diffuse fibrosis secondary to sys-
temic inflammation affecting both ventricles [32]. The cor-
relations, albeit weak observed between RVEF and LVEF/
left ventricular end-diastolic volume indexed (LVEDVI) in 
our study may also be explained by a degree of ventricular 
interdependence driven by obesity, typical of HFpEF popu-
lations [27].
Although the observational nature of our study precludes 
determination of causation, AF was significantly associated 
with RVD, suggesting a contributory role. Our findings of 
a higher AF prevalence are consistent with similar reports 
from previous HFpEF studies [8, 21, 22, 24]. However, it 
remains unclear whether AF is a cause or consequence of 
RVD in HF [20]. In HFrEF, RVD reportedly predicts future 
AF development [33]. Irrespective of HF subtype or aetiol-
ogy, AF in the setting of RVD is associated with haemo-
dynamic instability and with poorer outcomes [20, 34]. In 
the HFpEF population at large, development of AF confers 
a poorer quality of life [30], increases hospitalization rates 
and worsens mortality [30, 35].
Potential implications of our study
Our results, through the gold standard medium of CMR 
reinforce previous data that RVD is present in a significant 
minority of HFpEF. Furthermore, the presence of RVD 
alone and not necessarily more severe RVD is associated 
with heightened risk in HFpEF. RVD may drive recurrent 
HF hospitalizations and mortality. Identifying RVD is poten-
tially important for multiple reasons. HF hospitalizations 
are associated with significant morbidity and are a drain on 
healthcare resources [36]. Importantly, the prevalence of 
HFpEF is rising [3]. Understanding the mechanistic triggers 
for decompensation in HFpEF may also enable targeted ther-
apies (e.g. RV focused, management of AF). Whilst treat-
ments in unselected HFpEF patients have been neutral at 
best [37], one small study addressing pulmonary hyperten-
sion and RVD using a phosphodiesterase-5 inhibitor showed 
significant improvements in both cardiac haemodynamics 
and RV function [38].
Strengths and limitations
Our study is one of the largest to date evaluating RV per-
formance utilizing CMR and also benefits from having the 
longest follow-up to gauge the impact of RVD on clinical 
outcomes. Furthermore, we also have a comparator control 
group which is a particular strength. While RVEF measure-
ment is reportedly more reproducible using axial slice orien-
tations [39], we deliberately assessed RV function from the 
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short axis orientation since this is the method used routinely 
in clinical practice and our normative data were also derived 
using the same methodology [16]. Importantly, our tech-
nique yielded excellent intra- and inter-observer agreements.
This is a single centre, observational study and therefore 
should be replicated in additional cohorts. The association 
between RVD and outcome does not imply causality. We 
also do not have outcome data for deaths categorized as 
cardiovascular versus non-cardiovascular. Our definition of 
HFpEF was not in accordance with latest European Soci-
ety of Cardiology guidelines [40]. In particular diastolic 
dysfunction nor elevated natriuretic peptide levels were 
required for diagnosis. However, diastolic dysfunction at 
rest is reportedly absent in nearly one-third of contemporary 
HFpEF clinical trials [41] and conversely also identified in a 
significant proportion of asymptomatic elderly subjects [41]. 
Only a small minority of HFpEF patients in our study had 
BNP levels below ESC diagnostic thresholds (14%) which is 
unsurprising given the high burden of obesity observed [42]. 
During screening, all of our HFpEF patients subsequently 
enrolled had already had a diagnostic label of HFpEF made 
by Consultant Cardiologists during prior outpatient clin-
ics or following a HF hospitalization. Our control group 
included some hypertensive subjects and was therefore not 
totally devoid of cardiovascular disease. Since we excluded 
severe lung disease (which can cause RVD), our reported 
prevalence of RVD is probably lower than in the general 
HFpEF population at large. We did not calculate (derive) 
estimates of pulmonary artery pressures (PAP) or quantify 
tricuspid regurgitation severity using echocardiography or 
directly assess PAP using right heart catheterization.
Conclusions
RVD as assessed by CMR is present in a significant propor-
tion of HFpEF and is independently associated with death 
and or HF hospitalizations.
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